Amgen Inc.

AMGN · NASDAQ

Amgen reported FY2025 revenue of $36.75 billion and Q1 2026 revenue of $8.62 billion, with the official record tying the thesis to biologics scale, acquired-product integration, patent cliffs, pipeline execution, leverage and cash conversion.

Follow Add to Watchlist Ask Question

NASDAQ AMGN Coverage Bootstrap Amgen Inc.

Latest ReportMay 19, 2026Amgen: the post-Horizon biotech has to turn scale into deleveraging and pipeline proofView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Company filters1 of 1 reports match

Clear filters

Add tags

Selected tags

Nasdaq

Clear tags

Latest Thesis

Amgen: the post-Horizon biotech has to turn scale into deleveraging and pipeline proof

May 19, 2026Research reportSlides available

Read report Open slides Discussion (0)

Amgen Inc.the post-Horizon biotech has to turn scale into deleveraging andMay 19, 2026

Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Recent Reports

Compact report index for this company.

View all 1 reports ->

ReportTypeUpdatedReadActions

Amgen: the post-Horizon biotech has to turn scale into deleveraging and pipeline proofAmgen reported FY2025 revenue of $36.75 billion and Q1 2026 revenue of $8.62 billion, with the official record tying the thesis to biologics scale, acquired-product integration, patent cliffs, pipeline execution, leverage and cash conversion.NASDAQMay 19, 2026Research reportRead Slides